Press Releases

Press Releases

Schrödinger to Present at the Jefferies 2020 Virtual Healthcare Conference

NEW YORK --(BUSINESS WIRE)--May 28, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that members of the management team will participate in a fireside chat at the Jefferies
May 28, 2020

Schrödinger Reports First Quarter 2020 Financial Results and Recent Business Updates

Total revenue of $26.2 million and strong growth of 26% year-over-year Record software revenue of $23.8 million , up 28% year-over-year Raised $209.6 million in net proceeds through initial public offering Conference call today, Wednesday, May 13, 2020 at 8:30 a.m.
May 13, 2020

Schrödinger to Host First Quarter 2020 Financial Results Conference Call and Webcast

NEW YORK --(BUSINESS WIRE)--May 6, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that it will host a conference call and webcast on Wednesday, May 13, 2020 at 8:30 a.m.
May 6, 2020

Schrödinger Strengthens Board of Directors with Appointments of Jeffrey Chodakewitz, M.D., and Gary Ginsberg

NEW YORK --(BUSINESS WIRE)--May 4, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced the appointments of Jeffrey A. Chodakewitz , M.D., and Gary Ginsberg to its Board of
May 4, 2020

Schrödinger Announces Expanded Collaboration with AstraZeneca to Extend Computational Modeling Solutions to Biologics

NEW YORK --(BUSINESS WIRE)--Mar. 23, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced an expanded collaboration with AstraZeneca focused on refining a biologics modeling
March 23, 2020

Schrödinger Taps Google Cloud’s High-Performance Compute (HPC) Solution to Bolster Its Drug Discovery Efforts

Three-year deal will enable broader chemical exploration and accelerate advanced molecular modeling across internal and collaborative programs NEW YORK --(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced it has entered into a three-year agreement with Google Cloud to substantially
March 2, 2020

Schrödinger Announces Closing of Initial Public Offering

NEW YORK --(BUSINESS WIRE)--Feb. 10, 2020-- Schrödinger, Inc. (the “Company”) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the closing of its initial public
February 10, 2020

Schrödinger Announces Pricing of Initial Public Offering

NEW YORK --(BUSINESS WIRE)--Feb. 5, 2020-- Schrödinger, Inc. (the “Company”) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the pricing of its initial public
February 5, 2020

Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery

NEW YORK--( BUSINESS WIRE )--Schrödinger and Bayer (BAYN: DE) today announced a five-year technology alliance to develop a comprehensive  de novo  design solution with the objective to accelerate the discovery of innovative high-quality drugs. The technology is expected to be capable of
January 8, 2020
Displaying 11 - 19 of 19
Back To Top